sellWeak cluster of 3
Dwight Moxie sold $41k of RVNC
CLO & GC at Revance Therapeutics, Inc.. 8,125 shares at an average of $5.04, traded Mar 18, 2024, filed Mar 19, 2024.
Warning score
36Value
$41k
8,125 shares
Holdings after
137,815
-6% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +6Trade size$41k at market
- 0Share of holdings soldSold 5.6% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001479290-24-000067, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 15, 2024 | FTax withholding Common Stock | -3,269 | $5.31 | $17k | 145,940 | Mar 19, 2024 |
| Mar 18, 2024 | SOpen-market sale Common Stock | -8,125 | $5.04 | $41k | 137,815 | Mar 19, 2024 |
Related signals
Other insiders at Revance Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | RVNCsell Revance Therapeutics, Inc. | David Hollander CMO & Global Therapeutics Lead | $16k 3,908 shares | -4% | |
| 15Weak | RVNCsell Revance Therapeutics, Inc. | Erica Jordan Chief Commercial Officer | $9,096 2,392 shares | -2% | |
| 43Moderate | Revance Therapeutics, Inc. | Tobin Schilke CFO | $47k 9,361 shares | -5% | |
| 41Moderate | Revance Therapeutics, Inc. | Dustin S Sjuts President | $46k 9,211 shares | -5% | |
| 37Weak | RVNCbuy Revance Therapeutics, Inc. | Mark J Foley CEO | $209k 30,000 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.